Amarin Corp Plcuk (AMRN) Goodwill & Intangibles (2012 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Goodwill & Intangibles of $32.1 million for Q1 2026, up 104.86% YoY from $15.7 million in Q1 2025, and up 140.04% sequentially from $13.4 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Goodwill & Intangibles (2012 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Goodwill & Intangibles across 15 years of filings, most recently posting $32.1 million for Q1 2026.
- In Q1 2026, Goodwill & Intangibles rose 104.86% year-over-year to $32.1 million; the TTM figure through Mar 2026 stood at $32.1 million (up 104.86% YoY), while the FY2025 annual figure was $13.4 million, down 59.73% from the prior year.
- Goodwill & Intangibles improved to $32.1 million in Q1 2026, from $13.4 million in the prior quarter.
- Over the last five years, Goodwill & Intangibles for AMRN reached as high as $33.2 million in Q4 2023 and fell as low as $13.4 million in Q4 2025.
- The 5-year median for Goodwill & Intangibles is $32.1 million (2022), against an average of $25.7 million.
- Annual changes were most pronounced in 2025 — Goodwill & Intangibles plunged 59.73% — and 2026, when it jumped 104.86%.
- A 5-year view of Goodwill & Intangibles shows it stood at $21.8 million in 2022, then surged by 52.38% to $33.2 million in 2023, then changed by 0.0% to $33.2 million in 2024, then sank by 59.73% to $13.4 million in 2025, then jumped by 140.04% to $32.1 million in 2026.
- According to Business Quant data, Goodwill & Intangibles over the past three periods registered $32.1 million, $13.4 million, and $14.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.08 Mn |
| Dec 31, 2025 | 13.37 Mn |
| Sep 30, 2025 | 14.07 Mn |
| Jun 30, 2025 | 14.93 Mn |
| Mar 31, 2025 | 15.66 Mn |
| Dec 31, 2024 | 33.19 Mn |
| Sep 30, 2024 | 33.19 Mn |
| Jun 30, 2024 | 33.19 Mn |
| Mar 31, 2024 | 18.58 Mn |
| Dec 31, 2023 | 33.19 Mn |
| Sep 30, 2023 | 32.86 Mn |
| Jun 30, 2023 | 20.38 Mn |
| Mar 31, 2023 | 32.86 Mn |
| Dec 31, 2022 | 21.78 Mn |
| Sep 30, 2022 | 32.08 Mn |
| Jun 30, 2022 | 32.08 Mn |
| Mar 31, 2022 | 22.91 Mn |
| Dec 31, 2021 | 32.08 Mn |
| Sep 30, 2021 | 32.08 Mn |
| Jun 30, 2021 | 32.08 Mn |